Dean J Kereiakes

Summary

Publications

  1. pmc Olmesartan/amlodipine/hydrochlorothiazide in participants with hypertension and diabetes, chronic kidney disease, or chronic cardiovascular disease: a subanalysis of the multicenter, randomized, double-blind, parallel-group TRINITY study
    Dean J Kereiakes
    The Christ Hospital Heart and Vascular Center at the Christ Hospital, Cincinnati, OH, USA
    Cardiovasc Diabetol 11:134. 2012
  2. doi request reprint Longitudinal stent deformation: quantitative coronary angiographic analysis from the PERSEUS and PLATINUM randomised controlled clinical trials
    Dean J Kereiakes
    The Christ Hospital Heart and Vascular Center The Lindner Center for Research and Education at The Christ Hospital, Cincinnati, OH 45219, USA
    EuroIntervention 8:187-95. 2012
  3. doi request reprint Long-term efficacy and safety of triple-combination therapy with olmesartan medoxomil and amlodipine besylate and hydrochlorothiazide for hypertension
    Dean J Kereiakes
    Christ Hospital Heart and Vascular Center the Lindner Research Center, 2123 Auburn Avenue, Cincinnati, OH 45219, USA
    J Clin Hypertens (Greenwich) 14:149-57. 2012
  4. doi request reprint Clinical and angiographic outcomes after treatment of de novo coronary stenoses with a novel platinum chromium thin-strut stent: primary results of the PERSEUS (Prospective Evaluation in a Randomized Trial of the Safety and Efficacy of the Use of the TAXU
    Dean J Kereiakes
    Christ Hospital Heart and Vascular Center The Lindner Center for Research and Education at The Christ Hospital, Cincinnati, Ohio 45219, USA
    J Am Coll Cardiol 56:264-71. 2010
  5. doi request reprint Effect of an olmesartan medoxomil-based treatment algorithm on systolic blood pressure in patients with stage 1 or 2 hypertension: a randomized, double-blind, placebo-controlled study
    Dean J Kereiakes
    The Christ Hospital Heart and Vascular Center The Carl and Edyth Lindner Center for Research and Education at The Christ Hospital, Cincinnati, Ohio 45219, USA
    Am J Cardiovasc Drugs 10:239-46. 2010
  6. doi request reprint Comparison of everolimus-eluting and paclitaxel-eluting coronary stents in patients undergoing multilesion and multivessel intervention: the SPIRIT III (A Clinical Evaluation of the Investigational Device XIENCE V Everolimus Eluting Coronary Stent System
    Dean J Kereiakes
    Christ Hospital Heart and Vascular Center the Lindner Research Center, 2123 Auburn Avenue, Cincinnati, OH 45129, USA
    JACC Cardiovasc Interv 3:1229-39. 2010
  7. doi request reprint Efficacy of an olmesartan medoxomil-based treatment algorithm in patients with hypertension and type 2 diabetes: analysis of diurnal blood pressure control as assessed by 24-hour ambulatory blood pressure monitoring
    Dean J Kereiakes
    The Carl and Edyth Lindner Center for Research and Education at The Christ Hospital, 2123 Auburn Avenue, Suite 424, Cincinnati, OH 45219, USA
    Ther Adv Cardiovasc Dis 4:285-93. 2010
  8. doi request reprint Outcomes in diabetic and nondiabetic patients treated with everolimus- or paclitaxel-eluting stents: results from the SPIRIT IV clinical trial (Clinical Evaluation of the XIENCE V Everolimus Eluting Coronary Stent System)
    Dean J Kereiakes
    The Christ Hospital Heart and Vascular Center and The Carl and Edyth Lindner Center for Research and Education, Cincinnati, Ohio 45219, USA
    J Am Coll Cardiol 56:2084-9. 2010
  9. doi request reprint Predictors of death or myocardial infarction, ischaemic-driven revascularisation, and major adverse cardiovascular events following everolimus-eluting or paclitaxel-eluting stent deployment: pooled analysis from the SPIRIT II, III, IV and COMPARE trials
    Dean J Kereiakes
    The Christ Hospital Heart and Vascular Center The Lindner Research Center, Cincinnati, Ohio 45219, USA
    EuroIntervention 7:74-83. 2011
  10. pmc Seated cuff blood pressure-lowering efficacy of an olmesartan medoxomil-based treatment regimen in patients with type 2 diabetes mellitus
    Dean J Kereiakes
    The Christ Hospital Heart and Vascular Center The Carl and Edyth Lindner Center for Research and Education, Cincinnati, OH 45219, USA
    Drugs R D 11:251-7. 2011

Detail Information

Publications67

  1. pmc Olmesartan/amlodipine/hydrochlorothiazide in participants with hypertension and diabetes, chronic kidney disease, or chronic cardiovascular disease: a subanalysis of the multicenter, randomized, double-blind, parallel-group TRINITY study
    Dean J Kereiakes
    The Christ Hospital Heart and Vascular Center at the Christ Hospital, Cincinnati, OH, USA
    Cardiovasc Diabetol 11:134. 2012
    ..Patients with hypertension and cardiovascular disease (CVD), diabetes, or chronic kidney disease (CKD) usually require two or more antihypertensive agents to achieve blood pressure (BP) goals...
  2. doi request reprint Longitudinal stent deformation: quantitative coronary angiographic analysis from the PERSEUS and PLATINUM randomised controlled clinical trials
    Dean J Kereiakes
    The Christ Hospital Heart and Vascular Center The Lindner Center for Research and Education at The Christ Hospital, Cincinnati, OH 45219, USA
    EuroIntervention 8:187-95. 2012
    ..This analysis assesses the incidence of longitudinal stent deformation in three stent platforms...
  3. doi request reprint Long-term efficacy and safety of triple-combination therapy with olmesartan medoxomil and amlodipine besylate and hydrochlorothiazide for hypertension
    Dean J Kereiakes
    Christ Hospital Heart and Vascular Center the Lindner Research Center, 2123 Auburn Avenue, Cincinnati, OH 45219, USA
    J Clin Hypertens (Greenwich) 14:149-57. 2012
    ..6/100.7 mm Hg (baseline BP at randomization) to 125.0 to 136.8 mm Hg/77.8 to 82.5 mm Hg, depending on treatment. Long-term treatment with OM/AML/HCTZ was well tolerated and effective with no new safety concerns...
  4. doi request reprint Clinical and angiographic outcomes after treatment of de novo coronary stenoses with a novel platinum chromium thin-strut stent: primary results of the PERSEUS (Prospective Evaluation in a Randomized Trial of the Safety and Efficacy of the Use of the TAXU
    Dean J Kereiakes
    Christ Hospital Heart and Vascular Center The Lindner Center for Research and Education at The Christ Hospital, Cincinnati, Ohio 45219, USA
    J Am Coll Cardiol 56:264-71. 2010
    ....
  5. doi request reprint Effect of an olmesartan medoxomil-based treatment algorithm on systolic blood pressure in patients with stage 1 or 2 hypertension: a randomized, double-blind, placebo-controlled study
    Dean J Kereiakes
    The Christ Hospital Heart and Vascular Center The Carl and Edyth Lindner Center for Research and Education at The Christ Hospital, Cincinnati, Ohio 45219, USA
    Am J Cardiovasc Drugs 10:239-46. 2010
    ..The aim of this study was to analyze the magnitude of SBP reductions and the achievement of individual SBP targets in the original BENIFORCE study...
  6. doi request reprint Comparison of everolimus-eluting and paclitaxel-eluting coronary stents in patients undergoing multilesion and multivessel intervention: the SPIRIT III (A Clinical Evaluation of the Investigational Device XIENCE V Everolimus Eluting Coronary Stent System
    Dean J Kereiakes
    Christ Hospital Heart and Vascular Center the Lindner Research Center, 2123 Auburn Avenue, Cincinnati, OH 45129, USA
    JACC Cardiovasc Interv 3:1229-39. 2010
    ..We evaluated outcomes following XIENCE V everolimus-eluting stent (EES) compared with the Taxus Express(2) paclitaxel-eluting stent (PES) in patients undergoing multilesion and multivessel intervention...
  7. doi request reprint Efficacy of an olmesartan medoxomil-based treatment algorithm in patients with hypertension and type 2 diabetes: analysis of diurnal blood pressure control as assessed by 24-hour ambulatory blood pressure monitoring
    Dean J Kereiakes
    The Carl and Edyth Lindner Center for Research and Education at The Christ Hospital, 2123 Auburn Avenue, Suite 424, Cincinnati, OH 45219, USA
    Ther Adv Cardiovasc Dis 4:285-93. 2010
    ..Secondary, prespecified analysis of a single-arm, open-label study evaluating the efficacy of olmesartan medoxomil (OM) plus hydrochlorothiazide (HCTZ) in patients with hypertension and type 2 diabetes...
  8. doi request reprint Outcomes in diabetic and nondiabetic patients treated with everolimus- or paclitaxel-eluting stents: results from the SPIRIT IV clinical trial (Clinical Evaluation of the XIENCE V Everolimus Eluting Coronary Stent System)
    Dean J Kereiakes
    The Christ Hospital Heart and Vascular Center and The Carl and Edyth Lindner Center for Research and Education, Cincinnati, Ohio 45219, USA
    J Am Coll Cardiol 56:2084-9. 2010
    ....
  9. doi request reprint Predictors of death or myocardial infarction, ischaemic-driven revascularisation, and major adverse cardiovascular events following everolimus-eluting or paclitaxel-eluting stent deployment: pooled analysis from the SPIRIT II, III, IV and COMPARE trials
    Dean J Kereiakes
    The Christ Hospital Heart and Vascular Center The Lindner Research Center, Cincinnati, Ohio 45219, USA
    EuroIntervention 7:74-83. 2011
    ....
  10. pmc Seated cuff blood pressure-lowering efficacy of an olmesartan medoxomil-based treatment regimen in patients with type 2 diabetes mellitus
    Dean J Kereiakes
    The Christ Hospital Heart and Vascular Center The Carl and Edyth Lindner Center for Research and Education, Cincinnati, OH 45219, USA
    Drugs R D 11:251-7. 2011
    ..1%. Conclusions: An olmesartan medoxomil ± HCTZ treatment regimen significantly reduced BP from baseline in patients with hypertension and type 2 diabetes. Clinical Trials Registration: ClinicalTrials.gov identifier: NCT00403481...
  11. pmc A prospective evaluation of the safety and efficacy of the TAXUS Element paclitaxel-eluting coronary stent system for the treatment of de novo coronary artery lesions: design and statistical methods of the PERSEUS clinical program
    Dominic J Allocco
    Boston Scientific Corporation, One Boston Scientific Place, Natick, MA 01760, USA
    Trials 11:1. 2010
    ..The stent is intended to have enhanced radiopacity and improved deliverability compared to other paclitaxel-eluting stents. The safety and efficacy of the TAXUS Element stent are being evaluated in the pivotal PERSEUS clinical trials...
  12. ncbi request reprint Improving adjunctive pharmacotherapy for primary percutaneous coronary intervention in ST-segment elevation myocardial infarction: beyond the HORIZONS-AMI trial
    Dean J Kereiakes
    The Christ Hospital Heart and Vascular Center The Carl and Edyth Lindner Center for Research and Education, Cincinnati, OH, USA
    Rev Cardiovasc Med 10:72-82. 2009
    ....
  13. doi request reprint Peri-infarct pacing with CRT in the early postinfarct phase to attenuate long-term remodeling
    Eugene S Chung
    The Christ Hospital Heart and Vascular Center, The Ohio Heart and Vascular Center, The Lindner Center, Cincinnati, OH, USA
    J Cardiovasc Transl Res 2:126-9. 2009
    ..MENDMI will help to determine whether chronic application of peri-infarct pacing provides structural and clinical benefits and will help in the design of further investigations to modify postinfarction ventricular remodeling...
  14. doi request reprint A novel filter-based distal embolic protection device for percutaneous intervention of saphenous vein graft lesions: results of the AMEthyst randomized controlled trial
    Dean J Kereiakes
    Christ Hospital Heart and Vascular Center, Cincinnati, Ohio, USA
    JACC Cardiovasc Interv 1:248-57. 2008
    ..g., GuardWire, Medtronic Vascular/FilterWire EZ, Boston Scientific, Natick, Massachusetts) during percutaneous coronary intervention (PCI) of degenerative saphenous vein grafts (SVG)...
  15. doi request reprint The effects of an olmesartan medoxomil-based treatment algorithm on 24-hour blood pressure levels in elderly patients aged 65 and older
    Dean J Kereiakes
    The Christ Hospital Heart and Vascular Center and the Carl and Edyth Lindner Center for Research and Education at The Christ Hospital, Cincinnati, OH, USA
    J Clin Hypertens (Greenwich) 11:411-21. 2009
    ..2%), and headache (1.1%), were observed in 11.8% of patients. An OM-based treatment algorithm effectively lowers BP in an elderly patient population throughout the 24-hour dosing interval without compromising tolerability...
  16. ncbi request reprint Microvolt T-wave alternans identifies patients with ischemic cardiomyopathy who benefit from implantable cardioverter-defibrillator therapy
    Theodore Chow
    The Lindner Clinical Trial Center at the Christ Hospital and the Ohio Heart and Vascular Center, Cincinnati, Ohio, USA
    J Am Coll Cardiol 49:50-8. 2007
    ....
  17. ncbi request reprint Early revascularization and ACC/AHA guideline-compliant medical management improve left ventricular function and short-term prognosis in patients presenting with acute myocardial infarction and severe left ventricular dysfunction
    John J Young
    The Ohio Heart and Vascular Center, The Lindner Center for Research and Education at The Christ Hospital, Cincinnati, Ohio, USA
    J Invasive Cardiol 18:540-3. 2006
    ..We sought to determine the impact of contemporary treatment strategies on LV function and prognosis in patients with MI and severe LV dysfunction...
  18. doi request reprint Propensity-matched patient-level comparison of the TAXUS Liberté and TAXUS element (ION) paclitaxel-eluting stents
    Dean J Kereiakes
    The Christ Hospital Heart and Vascular Center The Lindner Center for Research and Education at The Christ Hospital, Cincinnati, Ohio, USA
    Am J Cardiol 108:828-37. 2011
    ..Stent platform-related variables may influence clinical outcomes after drug-eluting stent use despite similar polymer and drug elution. Differences in adjunctive pharmacotherapy and/or stenting technique may also be contributory...
  19. ncbi request reprint The truth and consequences of the COURAGE trial
    Dean J Kereiakes
    Christ Hospital Heart and Vascular Center the Lindner Research Center, Cincinnati, Ohio 45219, USA
    J Am Coll Cardiol 50:1598-603. 2007
    ..An in-depth analysis of the COURAGE trial design and execution is provided...
  20. ncbi request reprint Efficacy and safety of olmesartan medoxomil and hydrochlorothiazide compared with benazepril and amlodipine besylate
    Dean J Kereiakes
    The Christ Hospital Heart and Vascular Center and the Lindner Research Center, Cincinnati, Ohio 45219, USA
    Am J Cardiovasc Drugs 7:361-72. 2007
    ..Accordingly, combinations of two drugs with different mechanisms of antihypertensive action are widely used...
  21. ncbi request reprint Pharmacologic reperfusion strategies for the treatment of ST-segment elevation myocardial infarction
    John J Young
    Lindner Center for Research and Education, Ohio Heart Health Center, Cincinnati, Ohio, USA
    Rev Cardiovasc Med 4:216-27. 2003
    ..This review focuses on the evolving pharmacologic treatment strategies for STEMI...
  22. ncbi request reprint Periprocedural and late consequences of overlapping Cypher sirolimus-eluting stents: pooled analysis of five clinical trials
    Dean J Kereiakes
    Heart Center of Greater Cincinnati and the Lindner Center for Research and Education at The Christ Hospital, Ohio Heart and Vascular Center Inc, Cincinnati, Ohio 45219, USA
    J Am Coll Cardiol 48:21-31. 2006
    ..The purpose of this research was to determine the relative safety and efficacy of multiple (> or =2) overlapping Cypher sirolimus-eluting stents (SES) (Johnson & Johnson, New Brunswick, New Jersey)...
  23. doi request reprint Comparison of ultrafiltration, nesiritide, and usual care in acute decompensated heart failure
    Cheryl Bartone
    Heart Center of Greater Cincinnati at The Christ Hospital and The Ohio Heart and Vascular Center, Cincinnati, OH, USA
    Congest Heart Fail 14:298-301. 2008
    ..These findings, as well as the effects on renal function and length of stay, need to be further evaluated in a prospective randomized study...
  24. ncbi request reprint A guide to drug use during percutaneous coronary intervention
    Joseph K Choo
    The Lindner Center for Research and Education, Cincinnati, Ohio 45219, USA
    Drugs 62:2589-601. 2002
    ....
  25. doi request reprint Peri-procedural platelet function and platelet inhibition in percutaneous coronary intervention
    Dean J Kereiakes
    Christ Hospital Heart and Vascular Center, Lindner Research Center, Cincinnati, Ohio 45219, USA
    JACC Cardiovasc Interv 1:111-21. 2008
    ....
  26. ncbi request reprint Microcirculatory effects of abciximab and eptifibatide: a critical appraisal
    Dean J Kereiakes
    The Lindner Center for Research and Education, 2123 Auburn Avenue, Suite 424, Cincinnati, OH 45219, USA
    J Invasive Cardiol 15:481-3. 2003
  27. ncbi request reprint Effects of GP IIb/IIIa inhibitors on vascular inflammation, coronary microcirculation, and platelet function
    Dean J Kereiakes
    Heart Center of Greater Cincinnati, Cincinnati, Ohio, USA
    Rev Cardiovasc Med 7:S3-11. 2006
    ....
  28. ncbi request reprint Adjunctive pharmacotherapy before percutaneous coronary intervention in non-ST-elevation acute coronary syndromes: the role of modulating inflammation
    Dean J Kereiakes
    The Lindner Center for Research and Education, 2123 Auburn Avenue, Suite 424, Cincinnati, Ohio 45219, USA
    Circulation 108:III22-7. 2003
    ....
  29. ncbi request reprint Platelet activation and progression to complications
    Dean J Kereiakes
    Heart Center of Greater Cincinnati and Lindner Center at Christ Hospital, Cincinnati, Ohio, USA
    Rev Cardiovasc Med 7:75-81. 2006
    ..In general, optimal periprocedural outcomes require high levels of platelet inhibition. Combined administration of antiplatelet therapies may produce additive or synergistic inhibition of platelet-mediated thrombosis...
  30. ncbi request reprint Pharmacoinvasive management of acute coronary syndrome in the setting of percutaneous coronary intervention: evidence-based, site- and spectrum-of-care strategies for optimizing patient outcomes in NSTE-ACS
    Dean J Kereiakes
    The Lindner Center for Research and Education, Ohio State University, Cincinnati, USA
    J Invasive Cardiol 15:536-53. 2003
  31. ncbi request reprint Ischemia is the critical determinant of revascularization benefit: an interventionalist's perspective of the COURAGE trial
    Dean J Kereiakes
    The Christ Hospital Heart and Vascular Center, Cincinnati, OH, USA
    Rev Cardiovasc Med 10:S45-52. 2009
    ..The evolution of both PCI technology (DES) and adjunctive pharmacology has improved the relative magnitude and durability of PCI benefit compared with medical therapy alone...
  32. ncbi request reprint Prognostic utility of microvolt T-wave alternans in risk stratification of patients with ischemic cardiomyopathy
    Theodore Chow
    The Lindner Clinical Trial Center at the Christ Hospital and the Ohio Heart and Vascular Center, Cincinnati, Ohio, USA
    J Am Coll Cardiol 47:1820-7. 2006
    ..The purpose of this study was to assess if microvolt T-wave alternans (MTWA) is an independent predictor of mortality in patients with ischemic cardiomyopathy...
  33. ncbi request reprint Platelet glycoprotein IIb/IIIa inhibitor use during percutaneous coronary intervention: IIb or Not IIb, what is the question?
    John J Young
    The Carl and Edyth Lindner Center for Research and Education, Cincinnati, OH 45219, USA
    J Invasive Cardiol 14:404-10. 2002
    ..Evidence in support of the presence, magnitude and possible mechanisms for abciximab survival advantage is herein reviewed...
  34. ncbi request reprint New drug-eluting stent platforms to prevent stent thrombosis
    Dean J Kereiakes
    Heart Center of Greater Cincinnati and Lindner Center at Christ Hospital, Cincinnati, Ohio, USA
    Rev Cardiovasc Med 8:S34-43. 2007
    ....
  35. ncbi request reprint Vascular brachytherapy boon or bust?
    Dean J Kereiakes
    Carl and Edyth Lindner Center for Research and Education, 2123 Auburn Ave, Suite 424, Cincinnati, Ohio 45219, USA
    Circulation 108:389-90. 2003
  36. ncbi request reprint Cost efficacy of platelet glycoprotein IIb/IIIa antagonists in clinical trials and clinical practice
    John J Young
    Carl and Edyth Lindner Center for Research and Education, Ohio Heart Health Center, Cincinnati, Ohio, USA
    J Interv Cardiol 15:115-20. 2002
  37. ncbi request reprint Contemporary issues in the cath lab. Introduction
    Dean J Kereiakes
    Heart Center of Greater Cincinnati, Cincinnati, Ohio, USA
    Rev Cardiovasc Med 7:S1-2. 2006
  38. ncbi request reprint Inflammation as a therapeutic target: a unique role for abciximab
    Dean J Kereiakes
    Ohio State University, The Lindner Center for Research and Education, and The Ohio Heart Health Center, Cincinnati, Ohio 45219, USA
    Am Heart J 146:S1-4. 2003
    ..Vascular inflammation represents the "final common pathway" for many disease processes and thus represents the "ultimate therapeutic target" for pharmacologic intervention...
  39. ncbi request reprint Platelet GP IIb/IIIa inhibition in unstable angina and non-ST segment elevation MI: application of the ACC/AHA guidelines
    John J Young
    The Lindner Center for Research Education, 2123 Auburn Ave, Suite 424, Cincinnati, OH 45219, USA
    J Invasive Cardiol 15:102-7; quiz 108. 2003
  40. ncbi request reprint Usefulness of a cobalt chromium coronary stent alloy
    Dean J Kereiakes
    The Lindner Center Ohio Heart Health Center, Cincinnati, Ohio 45219, USA
    Am J Cardiol 92:463-6. 2003
    ..7% of patients. This registry establishes the safety and efficacy of this alloy as a coronary stent platform...
  41. ncbi request reprint Point-of-care ecarin clotting time versus activated clotting time in correlation with bivalirudin concentration
    Ivan P Casserly
    Department of Cardiovascular Disease, Cleveland Clinic Foundation, Cleveland, OH, USA
    Thromb Res 113:115-21. 2004
    ..We sought to examine the correlation of the TIM-ECT test with bivalirudin concentration in patients undergoing percutaneous coronary intervention (PCI), and to compare the performance of this test with the current standard (i.e., ACT)...
  42. doi request reprint Risk stratification and timing of revascularization: which patients benefit from early versus later revascularization?
    Ian J Sarembock
    The Christ Hospital Heart and Vascular Center and The Lindner Research Center at The Christ Hospital, 2123 Auburn Avenue, Cincinnati, OH 45219, USA
    Curr Cardiol Rep 14:510-20. 2012
    ....
  43. ncbi request reprint Prophylactic abciximab in elective coronary stenting: results of a randomized trial
    Corrado Tamburino
    The Lindner Center for Research and Education, 2123 Auburn Avenue, Suite 424, Cincinnati, OH 45219, USA
    J Invasive Cardiol 14:72-9. 2002
    ..We characterized patients undergoing elective implantation of long or multiple overlapping coronary stents and determined the impact of abciximab administration on clinical and angiographic outcomes...
  44. ncbi request reprint Thrombosis and drug-eluting stents: a critical appraisal
    Dean J Kereiakes
    Lindner Center for Research and Education, Ohio Heart Health Center, Cincinnati, Ohio, USA
    Rev Cardiovasc Med 5:9-15. 2004
    ..Cumulative data for the Cypher stent do not suggest a propensity for thrombosis, but several caveats should be observed to enhance the safety of the device...
  45. ncbi request reprint Abciximab survival advantage following percutaneous coronary intervention is predicted by clinical risk profile
    Dean J Kereiakes
    Lindner Center for Research and Education and Ohio Heart Health Center, Cincinnati, Ohio, USA
    Am J Cardiol 90:628-30. 2002
  46. ncbi request reprint Safety of drug-eluting stents
    Dean J Kereiakes
    The Christ Hospital Heart and Vascular Center, The Lindner Research Center, Cincinnati, OH, USA
    Rev Cardiovasc Med 11:187-99; quiz 200. 2010
    ....
  47. ncbi request reprint Percutaneous coronary revascularization of diabetic patients in the era of drug-eluting stents
    Dean J Kereiakes
    Lindner Center for Research and Education, Ohio Heart and Vascular Center, Inc, Christ Hospital, Cincinnati, Ohio, USA
    Rev Cardiovasc Med 6:S48-58. 2005
    ..Nevertheless, continued improvement in DES delivery as well as optimal adjunctive pharmacotherapy and control of hyperglycemia will be required to achieve the best clinical outcomes following PCI with DES in patients with diabetes...
  48. ncbi request reprint Adjunctive antiplatelet therapy during rescue PCI
    John J Young
    Ohio Heart and Vascular Center, The Lindner Center, Christ Hospital, Cincinnati, Ohio, USA
    J Invasive Cardiol 18:63-4. 2006
  49. ncbi request reprint Successful exclusion of a left main coronary artery aneurysm with a PTFE-covered coronary stent
    John J Young
    The Lindner Center for Research and Education, 2123 Auburn Avenue, Suite 424, Cincinnati, OH 45219, USA
    J Invasive Cardiol 16:433-4. 2004
  50. ncbi request reprint Clinical guidelines and practice: in search of the truth
    Dean J Kereiakes
    Heart Center of Greater Cincinnati, Cincinnati, Ohio, USA
    J Am Coll Cardiol 48:1129-35; discussion 1136-8. 2006
    ..It is appropriate at this time to briefly review specific aspects of the American College of Cardiology/American Heart Association practice guidelines and the current process of care for acute ischemic heart disease...
  51. doi request reprint Relationship of a quality measure composite to clinical outcomes for patients with heart failure
    Eugene S Chung
    Christ Hospital and the Ohio Heart and Vascular Center, Cincinnati, Ohio, USA
    Am J Med Qual 23:168-75. 2008
    ..To determine whether compliance with heart failure performance measures (HFPMs) is associated with short-term outcome benefit...
  52. ncbi request reprint Feasibility of biventricular pacing in patients with recent myocardial infarction: impact on ventricular remodeling
    Eugene S Chung
    The Christ Hospital, Ohio Heart and Vascular Center, and the Lindner Clinical Trial Center, Cincinnati, OH 45219, USA
    Congest Heart Fail 13:9-15. 2007
    ..06). Delivery of biventricular therapy early after myocardial infarction appears safe and feasible and may attenuate subsequent LV dilation...
  53. ncbi request reprint Interpreting the COURAGE trial. PCI is no better than medical therapy for stable angina? Seeing is not believing
    Dean J Kereiakes
    The Christ Hospital Heart and Vascular Center, The Lindner Research Center, Cincinnati, OH 45219, USA
    Cleve Clin J Med 74:637-8, 640-2. 2007
  54. ncbi request reprint Durable clinical benefit following Sr90 Beta irradiation therapy for in-stent restenosis in high-volume community practice
    John J Young
    The Carl and Edith Lindner Center for Research and Education, the Ohio Heart Health Center and the Christ Hospital, Cincinnati, OH 45219, USA
    J Invasive Cardiol 15:9A-13A. 2003
    ..Revascularization in follow-up is predominantly due to progressive disease outside the radiated segment and aggressive secondary prevention, especially prolonged anti-platelet therapy, appear critical to long-term procedural success...
  55. ncbi request reprint Coronary small-vessel stenting in the era of drug elution
    Dean J Kereiakes
    Lindner Center for Research and Education, Ohio Heart Health Center, Cincinnati, Ohio, USA
    Rev Cardiovasc Med 5:S34-45. 2004
    ..DES specifically designed for small-vessel application will become the standard for small vessel PCI...
  56. ncbi request reprint Clinical and angiographic outcomes in diabetic patients following single or multivessel stenting in the COSTAR II randomized trial
    Dean J Kereiakes
    The Christ Hospital Heart and Vascular Center The Lindner Research Center, Cincinnati, OH 45219, USA
    J Invasive Cardiol 20:335-41. 2008
    ..The safety and efficacy of paclitaxel elution from a bioresorbable polymer has not been studied in diabetic patients...
  57. ncbi request reprint Low-molecular-weight heparin therapy for non-ST-elevation acute coronary syndromes and during percutaneous coronary intervention: an expert consensus
    Dean J Kereiakes
    Lindner Center for Research and Education and The Ohio Heart Health Center, Cincinnati, Ohio 45219, USA
    Am Heart J 144:615-24. 2002
    ....
  58. ncbi request reprint Health care on trial: America's medical malpractice crisis
    Dean J Kereiakes
    The Lindner Center for Research and Education Ohio Heart Health Center, 2123 Auburn Ave, Suite 424, Cincinnati, Ohio 45219, USA
    Circulation 109:2939-41. 2004
  59. ncbi request reprint Combination antiplatelet therapy following brachytherapy with restenting: it ain't over 'til the fat lady sings
    Dean J Kereiakes
    The Lindner Center for Research and Education Ohio Heart Health Center, 2123 Auburn Avenue, Suite 424, Cincinnati, OH 45219, USA
    J Invasive Cardiol 14:115-7. 2002
  60. ncbi request reprint A novel, low-profile filter-wire (Interceptor) embolic protection device during saphenous vein graft stenting
    John J Young
    The Lindner Center for Research and Education and The Ohio Heart Health Center, Cincinnati, Ohio, USA
    Am J Cardiol 95:511-4. 2005
    ..Major adverse cardiovascular events were observed in only 2 patients (7.7%) and angiographic flow grades were improved...
  61. ncbi request reprint Phase I drug and light dose-escalation trial of motexafin lutetium and far red light activation (phototherapy) in subjects with coronary artery disease undergoing percutaneous coronary intervention and stent deployment: procedural and long-term results
    Dean J Kereiakes
    The Lindner Center for Research and Education, 2123 Auburn Ave, Suite 424, Cincinnati, Ohio 45219, USA
    Circulation 108:1310-5. 2003
    ..We assessed the safety and tolerability of phototherapy (PT) with MLu in patients undergoing percutaneous coronary intervention with stent deployment...
  62. doi request reprint Does microvolt T-wave alternans testing predict ventricular tachyarrhythmias in patients with ischemic cardiomyopathy and prophylactic defibrillators? The MASTER (Microvolt T Wave Alternans Testing for Risk Stratification of Post-Myocardial Infarction Pat
    Theodore Chow
    Lindner Clinical Trial Center at The Christ Hospital, Cincinnati, Ohio 45219, USA
    J Am Coll Cardiol 52:1607-15. 2008
    ..The purpose of this trial was to determine whether microvolt T-wave alternans (MTWA) predicts ventricular tachyarrhythmic events (VTEs) in post-myocardial infarction patients with left ventricular ejection fraction (LVEF) < or =30%...
  63. ncbi request reprint Complex coronary intervention in the drug-eluting stent era. Introduction
    Dean J Kereiakes
    Lindner Center for Research and Education, Ohio Heart and Vascular Center, Inc, Christ Hospital, Cincinnati, Ohio, USA
    Rev Cardiovasc Med 6:S1-2. 2005
  64. ncbi request reprint Therapeutic substitution: guilty until proven innocent
    Dean J Kereiakes
    The Lindner Center for Research and Education Ohio Heart Health Center, 2123 Auburn Ave, Suite 424, Cincinnati, OH 45219, USA
    Circulation 108:2611-2. 2003
  65. ncbi request reprint Specialized centers and systems for heart attack care
    Dean J Kereiakes
    Christ Hospital Heart and Vascular Center, The Lindner Research Center, and Ohio State University, Cincinnati, OH 45219, USA
    Am Heart Hosp J 6:14-20. 2008
    ..This article reviews the rationale behind, as well as the issues inherent to, the development of systems of care for STEMI patients...
  66. ncbi request reprint Coil embolization of a circumflex coronary aneurysm at the time of percutaneous coronary stenting
    Dean J Kereiakes
    The Carl and Edyth Lindner Center for Research and Education, The Lindner Center, Cincinnati, Ohio 45219, USA
    Catheter Cardiovasc Interv 67:607-10. 2006
    ..We describe the percutaneous catheter-based approach to coil embolization of a circumflex coronary aneurysm at the time of obtuse marginal branch coronary stent deployment...
  67. ncbi request reprint Safety and tolerability of serial home infusions of nesiritide for advanced heart failure
    Eugene S Chung
    The Lindner Clinical Trial Center, The Christ Hospital, Cincinnati, Ohio, USA
    Am J Cardiol 97:1370-3. 2006
    ..In conclusion, serial home infusions of nesiritide in patients with advanced HF appear to be safe and well tolerated, but the efficacy of this therapeutic strategy requires definition in a larger, randomized trial...